Balstilimab

• Study aiming to compare the survival of patients with locally advanced or metastatic MSI/dMMR Esogastric adenocarcinomas treated by a combin… Recruiting
  2023-506291-28-00 Phase III 1 country Centre Leon Berard
• Pan-tumor neoadjuvant basket study of immune check-point inhibition and novel IO combinations (NEOASIS) Recruiting
  2023-505756-21-00 Phase II 1 country Netherlands Cancer Institute
• Window-of-opportunity umbrella platform trial of short-course pre-operative targeted treatments in patients with molecularly selected and re… Recruiting
  2022-501308-90-00 Phase II 1 country Fondazione GONO G.I.
• Phase 1/1b study to assess the drug OBT076 in patients with recurrent and/or metastatic CD205-positive solid tumors Recruiting
  2024-511884-27-00 Phase I (Other) 4 countries Oxford Biotherapeutics Limited
• Clinical study to investigate efficacy of Botensilimab (AGEN1181) as Monotherapy and in Combination with Balstilimab (AGEN2034) or Investiga… Ended
  2022-502065-23-00 Phase II 4 countries Agenus Inc.
• A study to evaluate the safety and efficacy of CR6086 in combination with balstilimab (AGEN2034), in patients with pretreated mismatch-repai… Ended
  2024-515446-16-00 Phase I/II 1 country Rottapharm Biotech S.r.l.
• A phase 2, open label study to evaluate safety and clinical activity of balstilimab in monotherapy in patients with advanced/metastatic non-… Ended
  2024-517380-22-00 Phase II 1 country Narodowy Instytut Onkologii Im. Marii Sklodowskiej-Curie Panstwowy Instytut Bada…
• Clinical study to investigate the efficacy of botensilimab (AGEN1181) in patients with advanced melanoma refractory to prior checkpoint inhi… Ended
  2022-500652-37-00 Phase II 5 countries Agenus Inc.

Showing 1–8 of 8 trials